Compare HLLY & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | KMDA |
|---|---|---|
| Founded | 1903 | 1990 |
| Country | United States | Israel |
| Employees | 1520 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.3M | 458.6M |
| IPO Year | N/A | 2013 |
| Metric | HLLY | KMDA |
|---|---|---|
| Price | $3.19 | $8.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $4.57 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 838.9K | 71.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.95 | $14.04 |
| Revenue Next Year | $5.75 | $7.99 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $5.54 |
| 52 Week High | $4.48 | $9.35 |
| Indicator | HLLY | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 46.87 |
| Support Level | $2.73 | $6.69 |
| Resistance Level | $4.24 | $8.88 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 1.29 | 5.88 |
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.